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Case Reports

Azathioprine-lnduced Reversible Severe Dyserythropoiesis as a
Cause of Anemia
Sundara B.K. Raman, MD,* Joseph P. Abraham, MD,^ Sheikh M. Saeed, MD,* and
Maria Sawdyk, MD^

A 43-year-old woman with a 20-year history of systemic lupus erythematosus was treated with
azathioprine for progressive complications ofthe disease. She developed pancytopenia within four
weeks after starting azathioprine therapy. Bone marrow examination showed marked dyserythropoiesis and varying degrees of marrow hypoplasia. Changes seen in normoblasts consisted of
nuclear buds, multinucleation, Howell-Jolly bodies, and abnormal mitoses. Azathioprine was
discontinued. Peripheral blood counts improved in the next four weeks. A progress bone marrow
examination six weeks later showed marked improvement in red blood cell abnormalities. An
additional bone marrow examination performed four months afier discontinuation of azathioprine
showed complete disappearance ofthe dyspoietic changes in the red cell precursors despite continued
clinical deterioration.
Three patients who were treated with azathioprine to prevent transplant rejection showed similar
dyspoietic changes in erythroid precursors associated with anemia. (Henry FordHosp MedJ
1986:34:202-6)

eripheral blood macrocytosis associated with macronormoblastic and megaloblastoid changes in bone marrow
has been well studied and reported in patients receiving
azathioprine. A few cases of red cell hypoplasia have also been
encountered. However, severe erythroid dyspoiesis in the absence of significant macrocytic anemia and megaloblastic
changes due to azathioprine are unusual findings. Our report
discusses a patient w i t h long-standing systemic lupus
erythematosus who developed such a complication with
azathioprine therapy.

P

Case Report
A 43-year-old woman with a 20-year history of systemic lupus
erythematosus was treated with corticosteroids and salicylates during
the eariy stages of her disease. Corticosteroids were given intermittently at that time. During the seven years before her admission to
Henry Ford Hospital in March 1982, she was treated regulariy with 3 to
5 mg/day of prednisone and one tablet three fimes daily of hydroxylchloroquine sulfate. Prednisone dosage was tapered in the early part
of 1982 because of side-effects. On admission she showed evidence of
vasospasm in the upper extremities.
The patient's medication was changed to 100 mg/day of azathioprine,
and prednisone and hydroxychloroquine sulfate were continued in low
doses. At this time the patient's hematology profile was as follows;
hemoglobin 12.4 g/dL; mean corpuscular volume (MCV) 92; WBC
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4,600/|JLL; differential white count of 54% polymorphonuclear neutrophil leukocytes (PMN), 6% bands, 29% lymphocytes, 6% monocytes, 3% eosinophils, and 2% basophils; and platelet count
175,000/p.L. Coagulation and chemical parameters were within normal
limits. Total protein was 5,1; albumin 2,7 and globulin 2.4; A;G ratio
was 1:1.
During the next month the patient's hemoglobin gradually fell from
12.4 to 8.4 g/dL; WBC count declined from 4,600 to l,400/|jiL; and
platelet count declined to 93,000/|xL. Her MCV gradually increased
and remained above 104. Peripheral blood smear showed modest macrocytosis and only slight megalocytosis. Differential white count
.showed 35% PMN, 5% bands, 38% lymphocytes, 15% monocytes, 4%
eosinophils, and 3% basophils.
A bone manow aspirate and biopsy at this time revealed 40% cellularity with a myeloid to erythroid (M:E) ratio of 0.5; I. Granulocytes
were slightly decreased with some left shift. Megakaryocytes were adequate. Erythroid precursors showed slight macronormoblastic changes
with only occasional megaloblasts, but a large number of erythroblasts
(37% of marrow hemopoietic elements) disclosed extensive nuclear
pleomorphic changes (Figs 1 through 5). Ham's test was negafive. and
osmotic fragility was normal.
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Ft'g 7—Section from bone marrow after onset ofpancytopenia showing prominent erythroid
islands with nuclear pleomorphism (arrows) (hematoxylin-eosin stain) (X400).

Fig 2—Binucleated erythroblasts were preponderant in the smears (Leishman's stain)
(XIOOO).
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Fig 3—Giant
(XlOOOf

multinucleated

erythroblasts

Azathioprine was discontinued, and the patient was maintained on
steroids. During the next six weeks her WBC, hemoglobin, and platelet
count rose to 6,000/pLL, 11.5 g/dL, and 154,000/|xL, respectively.
MCV was 100. A repeat bone marrow aspirate showed a marked
decrease in erythroid pleomorphic changes. Granulocytes were well

Eig 4—Large erythroblasts
(Leishman's stain) (XIOOO).
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with numerous

were frequently

seen (Leishman's

stain)

represented, and platelet-forming megakaryocytes were seen more frequently. M;E ratio was 1.6:1.
During the next four months the patient's general condition deteriorated progressively from her primary disease, and she developed thromboemboli and infectious complications. Her hemoglobin and platelet

nuclear buds were also frequently

seen
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Fig 5—An erythroid precursor showing multiple Howell-Jolly bodies (Leishman's
(XIOOO).

count remained low at l0.2g/dLand I23.000/|JLL. Total and differential
WBC counts were normal. A third bone marrow aspirate performed
lour months after discontinuation of azathioprine showed complete disappearance of dyspoietic changes in erythroblasts (Fig 6). The patient
died a month later of thromboembolic complications.

stain)

Discussion
Since its introduction and approved use for prevention of renal transplantation rejection, azathioprine has also been used in
the treatment of a number of diseases including autoimmune
disorders. Several toxic effects of the dmg have been reported.

Fig 6—Bone marrow aspirate seven months after discontinuation of azathioprine showing
essentially slightly macronormoblastic
erythrogenesis with no evidence of dyspoiesis
(Leishman's stain) (XIOOO).
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particulady those affecting the hematopoietic system. Wickramasinghe et al (1) described several renal transplant patients
who developed macrocytosis with megaloblastic changes in the
manow during azathioprine therapy. Macrocytosis with selective erythroid hypoplasia has also been observed in some patients (2-4). Later studies of the effect of azathioprine on the
marrow cell cycle revealed a marked increase in the early
polychromic normoblasts in the G2 phase of cell cycle (5) and
minimal change in granulocytic elements. Well-defined
chromosomal abnormalities were also demonstrated in
erythroblasts in 80% of the patients treated with azathioprine
(6). Azathioprine can cause a general suppression of bone marrow (7,8) with resulting pancytopenia.
Our patient developed only slight macrocytosis associated
with minimal megaloblastic changes and pancytopenia. Although minor nuclear abnormalities have been observed in association with megaloblastosis (2), the unique finding of severe
dyserythropoiesis in the absence of significant megaloblastosis
in our patient has not been previously described.
Changes seen in red cells and their precursors may be a result
of alterations in the kinetics of cell proliferation involving erythroid stem cells as well as more primitive hemopoietic stem cells
(5,9). The changes previously reported appear to develop slowly
as the dmg is continued. In our patient the severe changes occuned within a relatively short period after azathioprine therapy
was started, but disappeared within a few months after the dmg
was discontinued. Thus, our case differs significandy from the
usually observed findings. This peculiar occurrence could be
due to the presence of a clone of multipotent stem cells or
erythropoietic stem cells with an unusual sensitivity to azathioprine (9). This may also account for occasionally, rapidly developing generalized manow hypoplasia or selective red cell hypoplasia in patients on azathioprine therapy.
During the last three years we have studied three padents
receiving azathioprine to prevent transplant rejection. These patients developed anemia associated with moderate to severe dyserythropoietic changes in the manow.
One patient, a 30-year-old man who had had a kidney transplant for end-stage renal disease, was on azathioprine for six
weeks when he developed anemia as well as leukopenia. At
the time of the bone manow examination his hemoglobin was
5,2 g/dL; MCV was 82; and WBC was 2,800/|xL. Bone manow
examination showed moderate to marked dyspoietic changes in
the erythroid precursors. Megaloblastic changes were not seen.
Granulocytic cell line showed slight maturation anest at the neutrophil stage. Megakarocytes were adequate. The dosage of
azathioprine was reduced initially and then discontinued. During the next six weeks the patient's hemoglobin and WBC count
improved. A repeat bone manow examination at the end of six
weeks showed only minimal residual dyspoietic changes.
In another case, a 37-year-old man who had had a cadaver
kidney transplant was on azathioprine therapy to prevent organ
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rejection. Four weeks after initiation of the treatment, the patient
developed pancytopenia with a hemoglobin of 4.9 g/dL; WBC
of l,700/p,L; platelet count of 61,000/p,L; and MCV of 89. Bone
marrow examination showed mild maturation anest in granulocytes, decreased platelet production found by megakaryocytes, and significant erythroid dyspoiesis with minimal
megaloblastic cha/.ges. Approximately five weeks after discontinuation of azathioprine, the hematological parameters
improved, A follow-up bone marrow examination was not
performed.
Another patient was a 43-year-old man on azathioprine therapy to prevent rejection after a kidney transplant. Within a
month after therapy the patient developed anemia with a hemoglobin of 6.2 g/dL; MCV was high at 116; and WBC was
5,l00/|xL with a normal differential count. Platelet count was
31,000/|JLL. Bone marrow examination showed marked
erythroid dyspoiesis associated with moderate megaloblastic
changes. Megakaryocytes were adequate. The dosage of
azathioprine was initially reduced and later discontinued.
Within six weeks after discontinuation, the patient's hemoglobin and platelet count improved significandy. MCV fell to
98. A follow-up bone manow examination was not performed.
The limited observations reported here suggest that azathioprine can occasionally cause severe red cell dyspoiesis with resulting anemia in addition to causing macrocytosis and red cell
hypoplasia. The apparent reversibility of this complication indicates that close monitoring of such patients is mandatory.
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